Investor Relations — About iPS Cells

iPS Cells — Broadening the Possibilities of the Cell Business

The induced pluripotent stem cell (iPS cell) forms the central core of our company’s business. A pluripotent cell that can transform into any other type of cell, its commercialization has advanced since its discovery in 2006. The iPS cell’s uses include the screening process used in drug discovery (evaluating medicinal and toxic properties). Expectations are high for future possibilities, including its application to regenerative medicine.

iPS Cells

Cardiac muscle, nerves, liver, blood — iPS cells have the ability to differentiate into a variety of other cell types and can also be multiplied into great quantities, allowing their research to advance quickly around the world.

Generation of iPS cells

The Merits of iPS Cells

  • iPS cells can differentiate (transform) into any other type of cell.
  • iPS cells multiply readily.
  • iPS cells can be artificially produced from the cells of the patient himself/herself.
  • iPS cells need not suffer transplant rejection and raise no ethical concerns.


The Business of iPS Cells

1. Research Reagents

Research reagentsSupporting pluripotent cell research through the production and sale of specialized reagents
We produce and sell reagents used in research, centering on the research of iPS cells. Our offerings are specialized depending on the variety of cell, method of multiplication, and method of measurement used, and include culture fluids, dissociation solutions, preservation solutions, coatings, and antibodies. We also sell many variations based on the marker used to identify iPS cells.

Target customers:

  • Public research organizations, e.g. universities
  • Private research organizations, e.g. drug manufacturers

2. Drug Discovery Applications

Drug discovery applicationsEffective investigation of medicinal and toxic properties in drug discovery
REPROCELL produces and sells cells for use in drug discovery screening, including nerve cells, cardiac muscle cells, liver cells, Alzheimer’s disease model cells, and more. These can be used by manufacturing companies researching new drugs to effectively evaluate the medicinal and toxic properties of a candidate compound. Hopefully, they will also be able to largely replace animal testing in the future.

Target customers:

  • Public research organizations, e.g. universities
  • Private research organizations, e.g. drug manufacturers

3. Tailor-made Treatment

Tailor-made treatmentRealizing personalized treatment for individual patients
Research is advancing towards tailor-made treatment that allows the use of iPS cells derived from the patient’s own skin or blood to assist in examination and the evaluation of treatment compatibility. Technologies utilizing iPS cells may allow us to pinpoint the ideal medicine and dosage to treat a patient’s individual needs.

Target customers: patients and hospitals

4. Regenerative Medicine

Regenerative medicineThe next generation of regenerative medicine, free of the need for donors.
Until now, regenerative medicine has relied on human cells supplied by donors, the shortage of which has posed a challenge. Research is advancing on the development of technologies to solve this problem by creating cells for use in transplants using iPS cells instead. Hopes are high for the realization of a technologies that eliminates the dependency on donors.

Target customers: patients and hospitals


From research and drug development to regenerative medicine, the scope of REPROCELL’s business broadens alongside the applications of iPS cells.